Loading institutional data...
Loading institutional data...
Held by 252 of 5,944 reporting institutions (93th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $277.99 today, the market must believe free cash flow compounds 20.6%/yr for a decade (off $44M normalized FCF).
2-stage DCF · 0.01B shares · net debt $115M
mean 131.7% · volatility σ 242% · implied rate exceeded in 5/8 yrs
Central path = implied 20.6%/yr growth; shaded band = ±1σ (242%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 12%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $20M covers the $16M due within a year 1.3× over. Scheduled principal only (excludes interest & revolver draws). As of 2024-09-30 (10-Q).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~7.2% on $135M of debt.
Cash of $20M fully covers short-term debt of $13M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-14
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $602.8M 100.0% | $504.4M 100.0% | $400.1M 100.0% | $353.8M 100.0% | $206.3M 100.0% | $179.4M 100.0% | $198.4M 100.0% | $190.5M 100.0% | $147.8M 100.0% | $146.1M 100.0% |
| Cost of Revenue | $432.4M 71.7% | $357.7M 70.9% | $287.8M 71.9% | $263.5M 74.5% | $155.2M 75.2% | $134.7M 75.1% | $144.4M 72.8% | $142.1M 74.6% | $112.4M 76.0% | $111.5M 76.3% |
| Cost of Products | — | — | — | — | — | — | — | — | $112.4M 76.0% | $111.5M 76.3% |
| Gross Profit | $170.4M 28.3% | $146.7M 29.1% | $112.2M 28.1% | $90.3M 25.5% | $51.1M 24.8% | $44.7M 24.9% | $54.0M 27.2% | $48.3M 25.4% | $35.5M 24.0% | $34.6M 23.7% |
| Research & Development | $8.6M 1.4% | $10.4M 2.1% | $7.2M 1.8% | $9.3M 2.6% | $8.5M 4.1% | $8.2M 4.6% | $8.8M 4.4% | $10.5M 5.5% | $5.0M 3.4% | $1.3M 0.9% |
| Selling, General & Admin | $77.4M 12.8% | $62.2M 12.3% | $50.9M 12.7% | $45.8M 12.9% | $29.5M 14.3% | $27.5M 15.3% | $29.3M 14.7% | $27.7M 14.5% | $23.7M 16.0% | $24.1M 16.5% |
| Operating Income | $92.3M 15.3% | $80.9M 16.0% | $57.7M 14.4% | $55.4M 15.7% | $21.2M 10.3% | $16.7M 9.3% | $24.7M 12.5% | $19.6M 10.3% | $11.7M 7.9% | $12.2M 8.4% |
| Interest Expense | $9.8M 1.6% | $8.1M 1.6% | $3.6M 0.9% | $2.8M 0.8% | $39K 0.0% | $83K 0.0% | $674K 0.3% | $1.3M 0.7% | $50K 0.0% | $69K 0.0% |
| Interest & Investment Income | — | — | — | — | $49K 0.0% | $0 0.0% | $0 0.0% | $47K 0.0% | $216K 0.1% | $149K 0.1% |
| Other Income (Expense), net | -$21K -0.0% | $189K 0.0% | -$117K -0.0% | $81K 0.0% | $26K 0.0% | -$366K -0.2% | -$388K -0.2% | $64K 0.0% | $166K 0.1% | $80K 0.1% |
| Pretax Income | $82.5M 13.7% | $73.0M 14.5% | $53.9M 13.5% | $52.7M 14.9% | $21.2M 10.3% | $16.3M 9.1% | $23.6M 11.9% | $18.4M 9.7% | $11.9M 8.0% | $12.3M 8.4% |
| Income Tax Expense | $14.2M 2.4% | $14.0M 2.8% | $9.0M 2.2% | $10.9M 3.1% | $5.3M 2.6% | $2.9M 1.6% | $3.9M 2.0% | $4.1M 2.1% | $2.6M 1.8% | $4.3M 3.0% |
| Net Income | $68.3M 11.3% | $59.0M 11.7% | $44.9M 11.2% | $41.8M 11.8% | $15.9M 7.7% | $13.4M 7.5% | $19.8M 10.0% | $14.3M 7.5% | $9.2M 6.2% | $8.0M 5.5% |
| Per Share | ||||||||||
| EPS (Basic) | $8.87 | $7.69 | $5.89 | $5.52 | $2.11 | $1.79 | $2.66 | $1.95 | $1.27 | $1.11 |
| EPS (Diluted) | $8.75 | $7.58 | $5.83 | $5.45 | $2.09 | $1.77 | $2.63 | $1.93 | $1.26 | $1.10 |
| Weighted Avg Shares (Basic) | 7.7M | 7.7M | 7.6M | 7.6M | 7.5M | 7.5M | 7.4M | 7.3M | 7.2M | 7.2M |
| Weighted Avg Shares (Diluted) | 7.8M | 7.8M | 7.7M | 7.7M | 7.6M | 7.6M | 7.5M | 7.4M | 7.3M | 7.3M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
EOD close · as of 2026-09-14
No material risks flagged.
Where each multiple sits in its own 14-yr range · 91th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 74.6 | 72.8 | 75.1 | 75.2 | 74.5 | 71.9 | 70.9 | 71.7 |
| Gross Profit | 25.4 | 27.2 | 24.9 | 24.8 | 25.5 | 28.1 | 29.1 | 28.3 |
| R&D | 5.5 | 4.4 | 4.6 | 4.1 | 2.6 | 1.8 | 2.1 | 1.4 |
| SG&A | 14.5 | 14.7 | 15.3 | 14.3 | 12.9 | 12.7 | 12.3 | 12.8 |
| Operating Income | 10.3 | 12.5 | 9.3 | 10.3 | 15.7 | 14.4 | 16.0 | 15.3 |
| Income Tax | 2.1 | 2.0 | 1.6 | 2.6 | 3.1 | 2.2 | 2.8 | 2.4 |
| Net Income | 7.5 | 10.0 | 7.5 | 7.7 | 11.8 | 11.2 | 11.7 | 11.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on UFPT: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.27T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $999.5B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $641.1B | 24.1× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $463.1B | 110.9× | 33.1× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.4B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $347.5B | 29.0× | 20.1× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $254.0B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $231.3B | 34.6× | 30.0× | 5.2× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $205.6B | 26.8× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $181.7B | 21.6× | 19.9× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $179.5B | 27.7× | 19.4× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.5B | 20.4× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $143.7B | 40.3× | 29.8× | 5.8× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $134.2B | 48.0× | 36.9× | 13.3× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $132.0B | 33.9× | 28.9× | 11.0× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $130.4B | 18.5× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| LGVN | $121.6B | — | — | 101442.6× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $121.4B | 68.7× | 12.2× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| MDT | $120.1B | 25.1× | 12.7× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| SYK | $107.7B | 33.6× | 18.5× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $106.2B | 23.7× | 16.7× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $95.6B | 15.0× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $93.6B | 16.8× | 15.8× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $83.0B | 19.1× | 19.9× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| UFPT | $2.1B | 31.8× | 20.3× | 3.6× | 19.5% | 28.3% | 11.3% | 16.1% | 12.2% | 1.2× | 252 |
Peers = companies sharing UFPT's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.